The benefits of a rounded shape will be tracked during the study. Credit: Biotronik.

Biotronik has secured approval from the US Food and Drug Administration (FDA) for the use of its Acticor and Rivacor cardiac rhythm management (CRM) devices to treat heart arrhythmias.

These small 3 Tesla (3T) magnetic resonance (MR) conditional CRM devices have rounded edges to reduce skin pressure and help lower the risk of skin erosion. Their long battery lives ensure fewer replacement surgeries and reduce costs.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Biotronik president Ryan Walters said: “The Acticor and Rivacor device systems reflect Biotronik’s commitment to engineering solutions with a profound positive impact for patients, physicians and health systems.

“We remain focused on bringing cardiac solutions to the US market that streamline processes and improve the ability to deliver care without compromise.”

“We remain focused on bringing cardiac solutions to the US market that streamline processes.”

The Acticor collection leverages the company’s DX technology, which identifies silent atrial fibrillation without the need of an atrial lead. This prevents strokes and improves diagnostic accuracy.

The devices also enable dual-chamber supraventricular tachycardia (SVT) discrimination to prevent unnecessary shocks.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The Rivacor HF-T QP has flexible programming options, including 20 left ventricular (LV) pacing vectors and cardiac resynchronisation therapy (CRT) optimisation. This CRT AutoAdapt programming facilitates automatic adjustment to changes in patient conditions, allowing responsive care in real-time.

Both Acticor and Rivacor devices include Biotronik Home Monitoring, which is claimed to result in a 60% decrease of mortality due to heart failure and a 36% reduction in hospitalisation for worsening heart failure.

The devices detect when a patient enters a magnetic resonance imaging (MRI) machine and adjusts the therapy for the duration of the scan.

Biotronik plans to launch the Acticor and Rivacor systems in the US next month.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact